MSLN and neoplasm: The CAPAN-2-tumor-bearing mice showed comparable levels of infiltration of the anti-mesothelin CAR-T cells among all treatment groups: percentages of CD3+ cells were 43% for CAR-T cells only; 45% for CAR-T cells + 2 Gy x 1 fraction; 48% for CAR-T cells + 2 Gy x 2 fractions; 38% for CAR-T cells + 1Gy x 4 fractions; and 32% for CAR-T cells + 4Gy x 1 fraction (online Supplementary Figure 8).